1.	Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation Phase: Phase IV Type: Natural history/Epidemiology, Supportive care Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2007-005844-26, NCT00903188
2.	A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001LIC01, NCT01206764
3.	Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001JIL05, NCT01231659
4.	An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRAD001LDE36T, 2010-021370-11, NCT01266837
5.	RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001KDE37, EudraCT 2010-022273-34, 2010-022273-34, NCT01317615
6.	Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) Phase: Phase IV Type: Treatment Status: Active Age: 6 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001MIL04T, NCT01365468
7.	Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001LDE43, 2011-003416-23, NCT01514448
8.	Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001K24133E1, NCT01595009
9.	An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001YGB11, 2012-003689-41, NCT01743560
10.	Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: Not specifiec Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001C2X01B, NCT01789281
11.	Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001N2301, 2008-000498-40, NCT00790036
12.	CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 2007.489/32, NCT00799188
13.	Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Phase: Phase III Type: Tissue collection/Repository, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000668388, SWOG-S0931, S0931, NCT01120249
14.	A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRAD001RDE35T, NCT01248403
15.	Caphosol in Oral Mucositis Due to Targeted Therapy Phase: Phase III Type: Supportive care Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: Esperanz-002, NCT01265810
16.	Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001T2302, 2011-002887-26, NCT01524783
17.	4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Health services research, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001JDE49, NCT01626222
18.	S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000738280, S1207, U10CA032102, SWOG-S1207, NCT01674140
19.	Study of BMS-936558 vs. Everolimus in Pre-Treated Advanced Or Metastatic Clear-cell RCC Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA209-025, 2011-005132-26, NCT01668784
20.	Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With Poor Prognosis, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving 3 Years of Adjuvant Hormone Therapy Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: UNIRAD, 2012-003187-44, UC-0140/1208, NCT01805271
21.	Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC) Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 to 75 Sponsor: Other Protocol IDs: CRAD001C2453, NCT00390195
22.	RAD001 in Advanced Hepatocellular Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06-352, NCT00516165
23.	Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 4P-09-4, AVF3955s, CRAD001CUS2468, NCT00574769
24.	Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MC0886, NCI-2009-00934, 08-004746, CLBH589BUS17T, NCT00918333
25.	Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 040803, P30CA072720, CDR0000648116, 0220090058, CRAD001C2448;, CINJ-040803, NOVARTIS-CINJ-040803, NCT00934895